6 December 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
CBR Macrophage
Delivery
Breakthrough in Delivering
Chimeric Bait Receptors to Immune Cells Accelerates
Development
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage biopharmaceutical company, is
pleased to announce a breakthrough in its development of a novel
method for delivering Chimeric Bait Receptors ("CBR") to innate
immune cells such as macrophages and monocytes i.e. the white
myeloid blood cells that make up the body's first line of defence
against infections and responsible for the removal of diseased or
damaged cells. This innovative approach utilizes lentiviral vectors
(a laboratory constructed and modified retrovirus that can be used
to insert genetic material into cells) to achieve highly efficient
transduction of macrophages or monocytes, while maintaining
durable, long-lasting CBR expression in these cells. In more
simple terms, the new methodology will extend the efficacy as well
as the durability of CBR within transduced cells.
The Company believes that this
innovative approach to myeloid immune cell transduction will
significantly accelerate the development of CBR-based product
candidates, facilitating their progression into IND-enabling
studies.
The Company's first-class scientific
team continues to make good progress with CBR and, once sufficient
resources are provided, the Company anticipates moving new
CBR-based product candidates into clinical trials, bringing them
closer to addressing unmet medical needs.
Dr Vladislav Sandler, CEO &
Co-Founder of Hemogenyx Pharmaceuticals,
commented: "We are thrilled to
announce this critical advancement in our CBR platform, which
represents a significant step forward in our mission to develop
cutting-edge therapies for unmet medical needs. Overcoming the
challenges of efficiently delivering CBRs to myeloid immune cells
has been a key focus for our team, and this breakthrough
underscores their dedication and ingenuity We remain committed to
leveraging this technology to bring transformative therapies to the
clinic and, ultimately, to patients in need. Once sufficient
resources are available to CBR, we are confident in our ability to
translate these scientific breakthroughs into impactful
treatments."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014 (as it forms part
of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.